06826 HAOHAI BIOTEC
- 41.900
- +0.350+0.84%
HAOHAI BIOTEC News
昊海生物科技：2024年第一季度報告
[Stock Exchange Amendment] Jiang Wei sold 1.73 million A-shares of Haohai Biotechnology (06826.HK), worth about 156 million yuan
On April 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 29, on July 3, 2023, Jiang Wei sold $1.73 million A-shares of $Haohai Biotechnology (06826.HK) at an average price of 90.0 yuan (RMB, same unit), worth about 156 million yuan. After the sale, Jiang Wei's latest shareholding was 77.99 million shares, and the good position ratio dropped from 57.60% to 56.35%. Additional information: The 1,730,000 A-share shares of the listed corporation sold by Mr. Jiang Wei on July 3, 2023 are through the Shanghai Zhanze enterprise management partnership under his control
HAOHAI BIOTEC To Go Ex-Dividend On June 6th, 2024 With 1.10175 HKD Dividend Per Share And 0.4 Stock Dividend Per Share
April 27th - $HAOHAI BIOTEC(06826.HK)$ is trading ex-dividend on June 6th, 2024. Shareholders of record on June 7th, 2024 will receive 1.10175 HKD dividend per share and 0.4 stock dividend per sha
Haohai Biotechnology (06826) will pay a final dividend of 1 yuan per share on July 19
Haohai Biotechnology (06826) issued an announcement that it will be distributed on July 19, 2024 until 2024 until 2023...
Haohai Biotechnology (06826.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Haohai Biotechnology (06826.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Haohai Biotech (688366) First Coverage Report: Biomaterials Industry Leaders Build a Comprehensive Platform for Medical Devices+Medical and Aesthetic Consumption
The company is a leader in the biomaterials segment, opening up a development ceiling for incremental ophthalmology and medical and aesthetic business layouts. Established in 2007, Haohai Biotech is mainly engaged in R&D, production and sales of medical device products. The company uses a “self-development+acquisition” policy
昊海生物科技：董事會會議召開日期
Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceili
Minsheng Securities released a research report on April 17 stating that it gave Haohai Biotech (688366.SH) a recommended rating. The main reasons for the rating include: 1) the company is a leader in the biomaterials segment, opening the development ceiling for the incremental ophthalmology and medical aesthetic business layout; 2) the ophthalmology and medical aesthetic market continues to grow rapidly, driven by internal and external factors, and iterations of innovative products drive the sustainability of the industry's growth; 3) the company has a comprehensive business layout and strong competitiveness in the ophthalmology and aesthetic business. (Mainichi Keizai Shimbun)
HAOHAI BIOTEC: ANNUAL REPORT 2023
Tianfeng Securities released a research report on April 11 stating that it gave Haohai Biotech (688366.SH) a purchase rating. The main reasons for the rating include: 1) sales of hyaluronic acid products are growing rapidly, and the company's revenue grow
Tianfeng Securities released a research report on April 11 stating that it gave Haohai Biotech (688366.SH) a purchase rating. The main reasons for the rating include: 1) sales of hyaluronic acid products are growing rapidly, and the company's revenue growth is in line with expectations; 2) third-generation hyaluronic acid drives gross margin growth, and the fourth generation has already entered the post-filing stage; 3) the acquisition of all shares of Euroamerica, and the development of ophthalmic products is progressing in an orderly manner. (Mainichi Keizai Shimbun)
Haohai Biotech (688366): High-end hyaluronic acid is growing rapidly, and development of ophthalmic products is progressing in an orderly manner
Event: The company released its 2023 annual report. In 2023, it achieved operating income of 2,654 billion yuan, an increase of 24.59% over the previous year; achieved net profit of 416 million yuan, an increase of 130.58% over the previous year; achieved after deduction
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Haohai Biotechnology (06826): 526,400 A-share restricted shares will be listed and circulated on April 1
Haohai Biotechnology (06826) issued an announcement regarding the first grant of the 2021 A-share Restricted Stock Incentive Plan to the Ministry...
Haohai Biotech's hyaluronic acid is still a good business, but ophthalmology is more complicated
“Investor Network” Cai Jun's hyaluronic acid competition among the Three Musketeers of Medicine and Aesthetics is getting hotter and hotter. Recently, Haohai Biotech (688366.SH, hereinafter referred to as the “Company”) and Aimeike released their 2023 Annual Report. During the reporting period, the company's operating income and net profit attributable to shareholders of listed companies were 2,654 million yuan and 416 million yuan respectively, up 24.59% and 130.58% year-on-year respectively. In the same period, Aimeike's operating revenue and net profit attributable to shareholders of listed companies were 2.87 billion yuan and 1,858 billion yuan respectively, up 47.99% and 47.08% year-on-year respectively. It should be pointed out that doctors who love American customers
Haohai Biotechnology (06826) issued 526,400 A-shares under the Restricted Stock Incentive Plan
Haohai Biotechnology (06826) issued an announcement on March 26, 2024, based on restricted stocks in 2021...
Express News | Haohai Biotech: Completed cancellation of 3.296,500 H shares
Haohai Biotechnology (06826.HK) cancelled 3.296,500 repurchased shares on March 19
Gelonghui March 19 | Haohai Biotechnology (06826.HK) issued an announcement to cancel 3.296,500 repurchased shares on March 19, 2024.
Haohai Biotechnology (06826): 679,300 restricted shares were vested
Zhitong Finance App News, Haohai Biotechnology (06826) issued an announcement. On March 18, 2024, the company held the 21st meeting of the 5th board of directors to review the “Proposal on Granting Part 2 of the Company's 2021 A-share Restricted Stock Incentive Plan for the First Time to Meet the Vesting Conditions”. According to the authorization of the company's first extraordinary general meeting of shareholders in 2022, the first A-share class shareholders' meeting in 2022, and the first H-share class shareholders' meeting in 2022, the board of directors believes that the vesting conditions stipulated in the company's 2021 A-share restricted stock incentive plan for the first time granted a second vesting period have already been met
Express News | 191 companies were surveyed by institutions, and Jiejie Microelectronics was surveyed by 170 institutions
Analysis
Price Target
No Data
